JGC
NVO

J. Goldman & Co’s Novo Nordisk NVO Stock Holding History

J. Goldman & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$417K Sell
11,335
-8,464
-43% -$401K 0.01% 528
2025
Q4 		$1.01M Sell
19,799
-30,201
-60% -$1.54M 0.03% 387
2025
Q3 		$2.77M Buy
+50,000
New +$2.93M 0.07% 252
2024
Q2 		– Sell
-20,000
Closed -$2.57M – 550
2024
Q1 		$2.57M Buy
+20,000
New +$2.38M 0.08% 203

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

J. Goldman & Co's NVO Position: Q1 2026 in Review

J. Goldman & Co reduced its Novo Nordisk (NVO) stake by 43% in Q1 2026, selling an estimated $401K and leaving 11,335 shares worth $417K. The position accounts for 0.01% of the portfolio, ranked #528.

J. Goldman & Co first reported a position in NVO in Q1 2024 and has held it in 4 quarters since. The position peaked at $2.77M in Q3 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • J. Goldman & Co held 11,335 shares of Novo Nordisk worth $417K as of Q1 2026.
  • J. Goldman & Co sold 8,464 Novo Nordisk shares in Q1 2026, an estimated $401K.
  • Novo Nordisk made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #528 holding.
  • J. Goldman & Co first reported a position in Novo Nordisk in Q1 2024 and has held it in 4 quarters since.
  • J. Goldman & Co's Novo Nordisk position peaked at $2.77M in Q3 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.